Showing 8191-8200 of 9426 results for "".
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- AppForMyPatients Now Available: Personalized Apps for Aesthetic Practiceshttps://practicaldermatology.com/news/20140922-appformypatients_now_available_personalized_apps_for_aesthetic_practices/2459112/A new patent pending mobile app Nano 2.0 Business Press, LLC aims to allow dermatologists and plastic surgeons to meet the growing patient demand for mobile applications. AppForMyPatients is a software as a service (saas) platform for d
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- AMA Calls for Design Overhaul of Electronic Health Records to Improve Usabilityhttps://practicaldermatology.com/news/20140917-ama_calls_for_design_overhaul_of_electronic_health_records_to_improve_usability/2459115/The AMA has called for solutions to EHR systems that have neglected usability as a necessary feature. Physicians need better designed EHR systems, the AMA has responded by releasing a new framework outlining eight priorities for improving EHR usability to benefit caregivers and patients.<
- The ISDS Welcomes the Dermatology Community to Jerusalemhttps://practicaldermatology.com/news/20140917-the_international_society_for_dermatologic_surgery_welcomes_the_dermatology_community_to_jerusalem/2459116/The 35th Annual International Society for Dermatologic Surgery (ISDS) Congress will be held in Jerusalem from October 22-24, 2014. The ISDS will have the newest and latest techniques dermatologic surgery, skin cancer surgery, laser surgery, hair transplantation, varicose veins, lipolysis,
- Provectus: PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At ESMO 2014https://practicaldermatology.com/news/20140915-provectus_pv-10_clinical_data_on_the_treatment_of_melanoma_to_be_presented_at_esmo_2014/2459120/Provectus Biopharmaceuticals, Inc. will present clinical data on PV-10 at the European Society for Medical Oncology's 2014 Congress (ESMO) in Madrid, Spain. The presentation, titled "Subgroup efficacy in patients receiving intralesional rose bengal t
- Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc.https://practicaldermatology.com/news/20140910-cynosure_acquires_assets_of_rf_medical_device_manufacturer_ellman_international_inc/2459121/Cynosure, Inc., which specializes in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, has acquired the assets of Ellman International, Inc. for approximately $13.2 million in cash. In addition, Cynosure assumed certain contractual and current liab
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom
- Alphaeon to Acquire Clarion Medical Technologieshttps://practicaldermatology.com/news/20140909-alphaeon_to_acquire_clarion_medical_technologies/2459125/Alphaeon Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Clarion Medical Technologies Inc. entered into a definitive agreement for Alphaeon to acquire all of the outstanding shares and assets of Clarion, a provider of medical and aesthetic equipment and consumabl